Aptahem (APTA) Q2 2025 earnings summary

Executive summary

• Achieved strategic milestones in scientific, industrial, and business development, strengthening position for next phase.

• Initiated strategic partnership with Hongene Biotech to reduce manufacturing costs and improve sustainability for lead candidate Apta-1.

• Received formal expression of interest from a reputable European pharmaceutical company for potential partnership.

• Strengthened cash position through a rights issue subscribed to 49%, raising approximately 4.8 MSEK before costs.

• Preparing for a potential listing on a U.S. marketplace, such as Nasdaq, to broaden access to international investors.

Financial highlights

• Q2 2025 operating income: 792 KSEK (down from 1,314 KSEK year-over-year).

• Result after financial items for Q2: -1,357 KSEK (improved from -2,634 KSEK year-over-year).

• Earnings per share for Q2: -0.08 SEK (improved from -0.46 SEK year-over-year; share consolidation 100:1 in Q2 2024).

• Cash and cash equivalents at June 30, 2025: 1,781 KSEK (down from 3,597 KSEK year-over-year).

• Solid equity ratio at 97.83% (up from 95.93% year-over-year).

Outlook and guidance

• Focus on advancing Apta-1 to phase 2 clinical trials and securing partnerships.

• Strategic process underway for U.S. listing to enhance financing opportunities.

• Ongoing regulatory preparations, including applications to FDA PreCheck and CNPV pilot programs for accelerated review.